Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

GENE:

ERCC1 (Excision repair cross-complementation group 1)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related tests:

‹

Labcorp® Plasma Complete™

Labcorp® Plasma Complete™

›

ERCC1 overexpression	Colorectal Cancer	ERCC1 overexpression	Colorectal Cancer	oxaliplatin Resistant: C3 – Early Trials oxaliplatin Resistant : C3	oxaliplatin Resistant: C3 – Early Trials oxaliplatin Resistant : C3
ERCC1 overexpression	Sarcoma	ERCC1 overexpression	Sarcoma	doxorubicin hydrochloride + trabectedin Sensitive: C3 – Early Trials doxorubicin hydrochloride + trabectedin Sensitive : C3	doxorubicin hydrochloride + trabectedin Sensitive: C3 – Early Trials doxorubicin hydrochloride + trabectedin Sensitive : C3
ERCC1 overexpression	Soft Tissue Sarcoma	ERCC1 overexpression	Soft Tissue Sarcoma	trabectedin Sensitive: C3 – Early Trials trabectedin Sensitive : C3	trabectedin Sensitive: C3 – Early Trials trabectedin Sensitive : C3
ERCC1 K504Q	Osteosarcoma	ERCC1 K504Q	Osteosarcoma	cisplatin Resistant: C3 – Early Trials cisplatin Resistant : C3	cisplatin Resistant: C3 – Early Trials cisplatin Resistant : C3
ERCC1 N118N	Osteosarcoma	ERCC1 N118N	Osteosarcoma	cisplatin Resistant: C3 – Early Trials cisplatin Resistant : C3	cisplatin Resistant: C3 – Early Trials cisplatin Resistant : C3
ERCC1 negative	HER2 Positive Breast Cancer	ERCC1 negative	HER2 Positive Breast Cancer	trastuzumab Resistant: C3 – Early Trials trastuzumab Resistant : C3	trastuzumab Resistant: C3 – Early Trials trastuzumab Resistant : C3
ERCC1 overexpression	HER2 Positive Breast Cancer	ERCC1 overexpression	HER2 Positive Breast Cancer	trastuzumab Resistant: C3 – Early Trials trastuzumab Resistant : C3	trastuzumab Resistant: C3 – Early Trials trastuzumab Resistant : C3
ERCC1 overexpression	Squamous Cell Carcinoma of Head and Neck	ERCC1 overexpression	Squamous Cell Carcinoma of Head and Neck	cisplatin + 5-fluorouracil Sensitive: C3 – Early Trials cisplatin + 5-fluorouracil Sensitive : C3	cisplatin + 5-fluorouracil Sensitive: C3 – Early Trials cisplatin + 5-fluorouracil Sensitive : C3
ERCC1 negative	Esophageal Adenocarcinoma	ERCC1 negative	Esophageal Adenocarcinoma	SOX Sensitive: C3 – Early Trials SOX Sensitive : C3	SOX Sensitive: C3 – Early Trials SOX Sensitive : C3
ERCC1 expression	Malignant Pleural Mesothelioma	ERCC1 expression	Malignant Pleural Mesothelioma	GC Sensitive: C3 – Early Trials GC Sensitive : C3	GC Sensitive: C3 – Early Trials GC Sensitive : C3
ERCC1 underexpression	Soft Tissue Sarcoma	ERCC1 underexpression	Soft Tissue Sarcoma	cisplatin + pemetrexed Sensitive: C3 – Early Trials cisplatin + pemetrexed Sensitive : C3	cisplatin + pemetrexed Sensitive: C3 – Early Trials cisplatin + pemetrexed Sensitive : C3
ERCC1 underexpression	Bladder Cancer	ERCC1 underexpression	Bladder Cancer	cisplatin + gemcitabine Sensitive: C3 – Early Trials cisplatin + gemcitabine Sensitive : C3	cisplatin + gemcitabine Sensitive: C3 – Early Trials cisplatin + gemcitabine Sensitive : C3